Finland · Delayed Price · Currency is EUR Herantis Pharma Oyj Statistics
Total Valuation
HEL:HRTIS has a market cap or net worth of EUR 54.21 million. The enterprise value is 49.68 million.
| Market Cap | 54.21M |
| Enterprise Value | 49.68M |
Important Dates
The next estimated earnings date is Friday, November 21, 2025.
| Earnings Date | Nov 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HEL:HRTIS has 24.09 million shares outstanding. The number of shares has increased by 17.58% in one year.
| Current Share Class | 24.09M |
| Shares Outstanding | 24.09M |
| Shares Change (YoY) | +17.58% |
| Shares Change (QoQ) | +19.51% |
| Owned by Insiders (%) | 13.00% |
| Owned by Institutions (%) | 40.69% |
| Float | 16.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 31.00 |
| P/TBV Ratio | 31.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.11 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.10, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.10 |
| Quick Ratio | 7.47 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.15 |
Financial Efficiency
Return on equity (ROE) is -287.85% and return on invested capital (ROIC) is -169.92%.
| Return on Equity (ROE) | -287.85% |
| Return on Assets (ROA) | -74.56% |
| Return on Invested Capital (ROIC) | -169.92% |
| Return on Capital Employed (ROCE) | -116.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -419,482 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.45% in the last 52 weeks. The beta is 0.22, so HEL:HRTIS's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +58.45% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 1.61 |
| Relative Strength Index (RSI) | 55.01 |
| Average Volume (20 Days) | 183,704 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.23M |
| Pretax Income | -5.45M |
| Net Income | -5.45M |
| EBITDA | n/a |
| EBIT | -5.23M |
| Earnings Per Share (EPS) | -0.25 |
Balance Sheet
The company has 4.56 million in cash and 25,000 in debt, giving a net cash position of 4.53 million or 0.19 per share.
| Cash & Cash Equivalents | 4.56M |
| Total Debt | 25,000 |
| Net Cash | 4.53M |
| Net Cash Per Share | 0.19 |
| Equity (Book Value) | 1.75M |
| Book Value Per Share | 0.07 |
| Working Capital | 4.48M |
Cash Flow
| Operating Cash Flow | -6.90M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HEL:HRTIS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.58% |
| Shareholder Yield | -17.58% |
| Earnings Yield | -10.06% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |